

ASX Announcement

11 June 2026

Investor Webinar

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) (“NSB” or the “Company”), an innovative Australian biotechnology company developing novel technologies targeted at immune mediated inflammatory diseases, is pleased to announce it will be holding an investor webinar on Tuesday, June 16, 2026, 11:30am AEST.

DATE/TIME: Tuesday, June 16, 2026, 11:30am AEST

SPEAKER(S): Mr Nathan Smith Chief Executive Officer, Dr Marian Sturm Chief Scientific Officer

REGISTRATION: https://janemorganmanagement-au.zoom.us/webinar/register/4417810511265/WN_wKw-4Af3Tym9zx_k1740yg

During the webinar CEO, Nathan Smith will provide an update on NSB’s recent progress, including the completion of its Special Access Program for StemSmart™ in fistulising Crohn’s disease.

Five patients received NSB’s StemSmart™ MSC product under the program, with all showing improvement and four out of five patients, representing 80%, achieving a successful Clinical Response, with no serious adverse events observed.

The webinar will also cover the Company’s planned Phase 2 clinical trial pathway, StemSmart’s commercial potential and upcoming milestones.

There will also be a Q&A with the presenters. NSB’s Chief Scientific Officer, Dr Marian Sturm, who pioneered the development of the StemSmart technology, will join Nathan for the Q&A session. A recording will be provided following the webinar.

This announcement is authorised by the CEO of NeuroScientific Biopharmaceuticals Ltd.

For more information, please contact:

Nathan Smith

Chief Executive Officer

NeuroScientific Biopharmaceuticals Ltd

ir@neuroscientific.com

Jane Morgan

Investor & Media Relations

Jane Morgan Management

jm@janemorganmanagement.com.au

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company’s research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.

Targeting Crohn's Disease with StemSmart™ Technology

Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the progression to Phase 2 clinical trials to further evaluate safety and efficacy of its proprietary StemSmart technology in refractory and fistulising Crohn's disease — severe and treatment-resistant forms of the condition. These clinical trials are supported by the favourable outcomes of the previous successful Phase 2 clinical trial in refractory Crohn's disease and the recent announcement of 80% clinical response under the Company's Special Access Program in fistulising Crohn's disease. This initiative aligns with NSB's broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn's disease, for whom current therapies remain inadequate.